Adjuvant high dose rate brachytherapy for soft tissue sarcomas: initial experience report. J Contemp Brachytherapy 2011 Mar;3(1):3-10
Date
03/01/2011Pubmed ID
27877194Pubmed Central ID
PMC5108830DOI
10.5114/jcb.2011.21036Scopus ID
2-s2.0-79953663275 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
PURPOSE: Adjuvant high-dose-rate brachytherapy (HDRBT) offers advantages over low dose rate brachytherapy (LDRBT), although there are little data on local tumor control and treatment related toxicity. We report outcome in patients with primary, recurrent, and metastatic extremity and superficial trunk soft tissue sarcoma.
MATERIAL AND METHODS: Eleven patients (12 sites) with intermediate or high grade sarcoma were treated with adjuvant HDRBT following surgical resection. Patients were treated at 3.4 Gy fractions delivered twice daily to a total dose of 34 Gy (1 patient received 9 fractions).
RESULTS: With median follow-up of 20.8 months, 1 patient developed a local recurrence. 2-year local control and overall survival are 89% and 71%, respectively. Wound complications occurred in 3 sites. Two of the wound complications developed in the area of previous external beam radiotherapy (EBRT).
CONCLUSION: Surgical resection followed by HDRBT is associated with excellent early local tumor control and acceptable wound complication.
Author List
Bradley JA, Kleinman SH, Rownd J, King D, Hackbarth D, Whitfield R, Wang DAuthors
David M. King MD Chair, Professor in the Orthopaedic Surgery department at Medical College of WisconsinJason Rownd MS Instructor in the Radiation Oncology department at Medical College of Wisconsin
